An exercise intervention without weight loss decreases circulating interleukin-6 in lean and obese men with and without type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 56, Issue 3, 2007, Pages 332-338

  Dekker, Mark J ^a   Lee, SoJung ^b   Hudson, Robert ^b   Kilpatrick, Katherine ^b   Graham, Terry E ^a   Ross, Robert ^b   Robinson, Lindsay E ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AEROBIC EXERCISE; ARTICLE; BODY FAT; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INSULIN SENSITIVITY; KINESIOTHERAPY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; SITTING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADIPOSITY; ADULT; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; EXERCISE; FASTING; HUMANS; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; WEIGHT LOSS;

EID: 33846836936     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.10.015     Document Type: Article

References (37)

1. Yudkin J.S., Juhan-Vague I., Hawe E., Humphries S.E., di Minno G., Margaglione M., et al. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 53 (2004) 852-857
2. Tuomisto K., Jousilahti P., Sundvall J., Pajunen P., and Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor α as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost 95 (2006) 511-518
3. Bastard J.P., Maachi M., Van Nhieu J.T., Jardel C., Bruckert E., Grimaldi A., et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87 (2002) 2084-2089
4. Pickup J.C., Mattock M.B., Chusney G.D., and Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40 (1997) 1286-1292
5. Haffner S.M., D'Agostino Jr. R., Festa A., Bergman R.N., Mykkanen L., Karter A., et al. Low insulin sensitivity (S(i) = 0) in diabetic and nondiabetic subjects in the insulin resistance atherosclerosis study: is it associated with components of the metabolic syndrome and nontraditional risk factors?. Diabetes Care 26 (2003) 2796-2803
6. McLaughlin T., Abbasi F., Lamendola C., Liang L., Reaven G., Schaaf P., et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 106 (2002) 2908-2912
7. Bastard J.P., Pieroni L., and Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 16 (2000) 192-201
8. Mutch N.J., Wilson H.M., and Booth N.A. Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc 60 (2001) 341-347
9. Ross R., Aru J., Freeman J., Hudson R., and Janssen I. Abdominal adiposity and insulin resistance in obese men. Am J Physiol Endocrinol Metab 282 (2002) E657-E663
10. Miyazaki Y., Glass L., Triplitt C., Wajcberg E., Mandarino L.J., and DeFronzo R.A. Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 283 (2002) E1135-E1143
11. Ryan A.S., and Nicklas B.J. Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care 27 (2004) 1699-1705
12. Hamdy O., Ledbury S., Mullooly C., Jarema C., Porter S., Ovalle K., et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 26 (2003) 2119-2125
13. Esposito K., Pontillo A., Di Palo C., Giugliano G., Masella M., Marfella R., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289 (2003) 1799-1804
14. Lee S., Kuk J.L., Davidson L.E., Hudson R., Kilpatrick K., Graham T.E., et al. Exercise without weight loss is an effective strategy for obesity reduction in obese individuals with and without type 2 diabetes. J Appl Physiol 99 (2005) 1220-1225
15. Lee S., Hudson R., Kilpatrick K., Graham T.E., and Ross R. Caffeine ingestion is associated with reductions in glucose uptake independent of obesity and type 2 diabetes before and after exercise training. Diabetes Care 28 (2005) 566-572
16. Harris J., and Benedict F. A biometric study of basal metabolism in man (1919), Carnegie Institution of Washington, Washington (DC)
17. Ross R., Leger L., Morris D., de Guise J., and Guardo R. Quantification of adipose tissue by MRI: relationship with anthropometric variables. J Appl Physiol 72 (1992) 787-795
18. Janssen I., Katzmarzyk P.T., and Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 79 (2004) 379-384
19. Janssen I., Katzmarzyk P.T., and Ross R. Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. Arch Intern Med 162 (2002) 2074-2079
20. Pedersen B.K., Steensberg A., Fischer C., Keller C., Keller P., Plomgaard P., et al. Searching for the exercise factor: is IL-6 a candidate?. J Muscle Res Cell Motil 24 (2003) 113-119
21. Pedersen B.K., Steensberg A., Fischer C., Keller C., Keller P., Plomgaard P., et al. The metabolic role of IL-6 produced during exercise: is IL-6 an exercise factor?. Proc Nutr Soc 63 (2004) 263-267
22. Ziccardi P., Nappo F., Giugliano G., Esposito K., Marfella R., Cioffi M., et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105 (2002) 804-809
23. Monzillo L.U., Hamdy O., Horton E.S., Ledbury S., Mullooly C., Jarema C., et al. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res 11 (2003) 1048-1054
24. Kopp H.P., Kopp C.W., Festa A., Krzyzanowska K., Kriwanek S., Minar E., et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 23 (2003) 1042-1047
25. Kopp H.P., Krzyzanowska K., Mohlig M., Spranger J., Pfeiffer A.F., and Schernthaner G. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes Relat Metab Disord 29 (2005) 766-771
26. Taniguchi A., Fukushima M., Ohya M., Nakai Y., Yoshii S., Nagasaka S., et al. Interleukin 6, adiponectin, leptin, and insulin resistance in nonobese Japanese type 2 diabetic patients. Metabolism 55 (2006) 258-262
27. Carey A.L., Bruce C.R., Sacchetti M., Anderson M.J., Olsen D.B., Saltin B., et al. Interleukin-6 and tumor necrosis factor-α are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 47 (2004) 1029-1037
28. Park H.S., Park J.Y., and Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract 69 (2005) 29-35
29. Cushman M., Arnold A.M., Psaty B.M., Manolio T.A., Kuller L.H., and Burke G.L. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 112 (2005) 25-31
30. Koenig W., Lowel H., Baumert J., and Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 109 (2004) 1349-1353
31. Okita K., Nishijima H., Murakami T., Nagai T., Morita N., Yonezawa K., et al. Can exercise training with weight loss lower serum C-reactive protein levels?. Arterioscler Thromb Vasc Biol 24 (2004) 1868-1873
32. Marcell T.J., McAuley K.A., Traustadottir T., and Reaven P.D. Exercise training is not associated with improved levels of C-reactive protein or adiponectin. Metabolism 54 (2005) 533-541
33. Clifton P.M., Keogh J.B., Foster P.R., and Noakes M. Effect of weight loss on inflammatory and endothelial markers and FMD using two low-fat diets. Int J Obes (Lond) 29 (2005) 1445-1451
34. Dvorakova-Lorenzova A., Suchanek P., Havel P.J., Stavek P., Karasova L., Valenta Z., et al. The decrease in C-reactive protein concentration after diet and physical activity induced weight reduction is associated with changes in plasma lipids, but not interleukin-6 or adiponectin. Metabolism 55 (2006) 359-365
35. Yap S.H., Moshage H.J., Hazenberg B.P., Roelofs H.M., Bijzet J., Limburg P.C., et al. Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta 1091 (1991) 405-408
36. Sakkinen P.A., Wahl P., Cushman M., Lewis M.R., and Tracy R.P. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 152 (2000) 897-907
37. Kruszynska Y.T., Yu J.G., Olefsky J.M., and Sobel B.E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 49 (2000) 633-639